BlackRock Inc. Acquires 838,220 Shares of Medtronic PLC $MDT
BlackRock Inc. increased its stake in Medtronic PLC by 838,220 shares in the second quarter, bringing its total holdings to 114.02 million shares valued at $8.92 billion. Medtronic reported strong quarterly revenues of $9.81 billion and adjusted earnings of $1.55 per share, exceeding analyst expectations, and declared a quarterly dividend of $0.72 per share. Analysts generally maintain a "Moderate Buy" rating for Medtronic, with an average price target of $98.83.
E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM
E Fund Management Co. Ltd. has acquired 18,894 shares of DexCom, Inc. (NASDAQ:DXCM) worth approximately $1.27 million during the second quarter, making it one of several institutional investors to modify their holdings. DexCom reported strong quarterly earnings, surpassing analyst expectations with $0.70 EPS and $1.31 billion in revenue, reflecting a 13.1% year-over-year increase. Despite insider selling activity, analysts maintain a "Moderate Buy" consensus rating with an average price target of $88.71.
Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM
Edmond DE Rothschild Holding S.A. recently acquired a new position in DexCom, Inc. (NASDAQ:DXCM), purchasing 74,350 shares valued at approximately $5.01 million. This investment highlights significant institutional interest, with hedge funds and other institutional investors owning 97.75% of DexCom's stock. The article also details recent analyst ratings, insider trading activity, and DexCom's financial performance, including its latest quarterly earnings beat.
Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM
Deutsche Bank AG has acquired a new stake in DexCom, Inc. (NASDAQ:DXCM), purchasing over 2.4 million shares valued at approximately $164 million. This move makes Deutsche Bank AG a significant institutional holder with about 0.65% ownership. Other major institutional investors have also adjusted their holdings in DexCom, while several analysts maintain "Buy" or "Strong Buy" ratings for the medical device company.
Colrain Capital LLC Has $10.45 Million Position in Medtronic PLC $MDT
Colrain Capital LLC increased its stake in Medtronic PLC by 26.1% in the second quarter, now holding 132,354 shares valued at $10.45 million. Institutional investors collectively own 82.06% of Medtronic, which has a consensus "Moderate Buy" rating. The company recently exceeded earnings expectations, raised its dividend, but faces some analyst target reductions and insider selling.
Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM
Aurora Investment Counsel has acquired a new stake worth $2.34 million in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, making it their 25th largest position. Other institutional investors have also adjusted their holdings in DexCom, and analysts have set new price targets, with a consensus "Moderate Buy" rating and an average target price of $88.71. The article also notes recent insider stock sales by DexCom executives.
DexCom Data Scientist Salaries in Monroe, MI
The average DexCom Data Scientist in Monroe, MI, earns an annual total compensation of $138,000, which includes a base salary of $107,000 and a $31,000 bonus. This compensation is $8,495 higher than the national average for Data Scientists. The data, based on one salary record, also indicates that DexCom Data Scientists in Monroe, MI, rate their compensation fairly, with 88% receiving annual bonuses and 73% satisfied with their benefits.
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in DexCom, Inc. $DXCM
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, purchasing over 1.3 million shares valued at approximately $89.94 million. This makes Mitsubishi UFJ Asset Management Co. Ltd. a significant institutional holder, owning about 0.35% of DexCom. The article also highlights other institutional investments, analyst ratings, and recent insider stock sales, alongside DexCom's financial performance and company profile.
Plato Investment Management Ltd Buys Shares of 11,681 DexCom, Inc. $DXCM
Plato Investment Management Ltd recently acquired 11,681 shares of DexCom, Inc. (NASDAQ:DXCM), valued at approximately $782,000, as disclosed in their latest SEC filing. This acquisition is part of a trend where institutional investors hold a significant portion of DexCom's stock. The article also details DexCom's recent financial performance, including exceeding Q2 earnings estimates, and provides information on insider stock sales and analyst ratings.
Veritas Asset Management LLP Has $7.56 Million Stock Holdings in Medtronic PLC $MDT
Veritas Asset Management LLP has reduced its stake in Medtronic PLC by 40.6% in the second quarter, now holding 96,690 shares valued at $7.56 million. Despite this reduction, other institutional investors have increased their positions. Medtronic reported strong quarterly earnings, beating estimates with $1.55 EPS and $9.81 billion in revenue, and raised its quarterly dividend to $0.72 per share.
Medtronic PLC $MDT Position Reduced by Hedeker Wealth LLC
Hedeker Wealth LLC reduced its stake in Medtronic PLC (NYSE:MDT) by 36.6% in the second quarter, selling 17,444 shares and retaining 30,282 shares valued at $2,369,000. Other institutional investors showed mixed activity, with some increasing and others reducing their positions in MDT. Insider activity includes an EVP selling over 4,000 shares, and analysts have issued a "Moderate Buy" consensus rating with a target price of $98.83.
Journey Advisory Group LLC Grows Position in Medtronic PLC $MDT
Journey Advisory Group LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 2,312.5% in the second quarter, now owning 62,121 shares valued at $4.901 million. Other institutional investors also adjusted their positions in Medtronic, which has shown mixed sentiment from analysts regarding its valuation and near-term upside. Despite some insider selling and varying price targets, the company recently increased its quarterly dividend and reported stronger-than-expected earnings.
Fifth Third Bancorp Trims Position in Medtronic PLC $MDT
Fifth Third Bancorp reduced its stake in Medtronic PLC by 26.2% in the second quarter, selling 55,387 shares and retaining 155,772 shares valued at $12.2 million. Institutional investors hold 82.06% of Medtronic, which recently reported strong quarterly revenue and adjusted earnings, exceeding analyst expectations. The company also increased its quarterly dividend and maintains a "Moderate Buy" consensus rating from analysts, despite some recent price target adjustments.
Fox Run Management L.L.C. Increases Position in Medtronic PLC $MDT
Fox Run Management L.L.C. significantly increased its stake in Medtronic PLC (NYSE:MDT) by 364.9% in the second quarter, bringing its total holdings to 23,397 shares valued at $1.83 million. Other major institutional investors like Vanguard Group Inc., State Street Corp, and JPMorgan Chase & Co. also boosted their positions in Medtronic. The article also notes mixed sentiment among analysts and institutional investors, with recent news covering both positive aspects like market outperformance and dividend increases, and negative points such as CEO compensation and insider sales.
12,080 Shares in DexCom, Inc. $DXCM Bought by Alamar Capital Management LLC
Alamar Capital Management LLC has acquired a new position in DexCom, Inc. (NASDAQ:DXCM), purchasing 12,080 shares valued at approximately $814,000 during the second quarter. This move is part of broader institutional activity, with other firms also increasing or initiating positions in the medical device company. The article also notes recent insider selling by DexCom executives and provides an overview of analyst ratings, stock performance, and company financials.
Dexcom stock edges higher as Q1 2026 growth and CGM demand support valuation
Dexcom Inc. stock is trading higher in mid-August 2026, with shares up over 30% year-to-date, driven by strong Q1 2026 revenue and earnings growth in its continuous glucose monitoring business. The company reported adjusted EPS of $0.56 and revenue of $1.19 billion, exceeding analyst expectations. This performance, coupled with ongoing demand for CGM systems and institutional interest, supports investor confidence despite recent insider sales.
Performance Wealth Partners LLC Takes Position in DexCom, Inc. $DXCM
Performance Wealth Partners LLC has acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, purchasing 25,838 shares valued at approximately $1,740,000. Other institutional investors have also adjusted their holdings in the medical device company. Analyst ratings for DexCom are predominantly positive, with a consensus of "Moderate Buy" and an average target price of $88.71.
Medtronic PLC $MDT Holdings Increased by Willis Investment Counsel
Willis Investment Counsel increased its stake in Medtronic PLC (NYSE:MDT) by 5.7% during the second quarter, bringing its total holdings to 414,539 shares valued at $32.43 million. This makes Medtronic the 22nd largest holding for the firm, comprising 1.5% of its investment portfolio. Other institutional investors also adjusted their positions in Medtronic, which currently has a consensus rating of "Moderate Buy" and a target price of $98.83 from analysts.
Flputnam Investment Management Co. Makes New Investment in DexCom, Inc. $DXCM
Flputnam Investment Management Co. has reported a new investment in DexCom, Inc. (NASDAQ:DXCM), purchasing 15,705 shares valued at approximately $1.058 million during the second quarter. Other institutional investors also adjusted their holdings, and the article details recent insider stock sales and DexCom's financial performance. Analyst ratings for DexCom are predominantly "Buy" or "Strong Buy," with an average target price of $88.71.
GSA Capital Partners LLP Takes $1.33 Million Position in DexCom, Inc. $DXCM
GSA Capital Partners LLP has acquired a new stake of 19,820 shares in DexCom, Inc. valued at approximately $1.33 million during the second quarter. Other institutional investors also increased their holdings in DexCom, which currently has a "Moderate Buy" rating from analysts with a consensus target price of $88.71. Despite insider selling activity, the company reported strong earnings, beating analyst estimates for both EPS and revenue in its last quarter.
Global Retirement Partners LLC Purchases Shares of 20,784 DexCom, Inc. $DXCM
Global Retirement Partners LLC has acquired 20,784 shares of DexCom, Inc. (NASDAQ:DXCM) for approximately $1.4 million, with institutional investors now owning 97.75% of the company. Despite positive analyst ratings, a "Moderate Buy" consensus, and strong Q2 earnings that beat expectations, insiders have sold nearly 100,000 shares worth over $7 million in the past 90 days. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported $0.70 EPS and $1.31 billion in revenue, marking a 13.1% year-over-year increase.
DexCom Inc. stock underperforms Monday when compared to competitors
DexCom Inc. (DXCM) stock fell 1.10% on Monday, closing at $88.76, while the broader market also experienced a downturn with the S&P 500 Index and Dow Jones Industrial Average both declining. This marks the second consecutive day of losses for DexCom's stock.
Dexcom (NASDAQ: DXCM) legal chief sells stock under 10b5-1 plan
Michael Jon Brown, EVP Chief Legal Compliance Officer at Dexcom (NASDAQ: DXCM), sold 1,700 shares of common stock at $91.93 per share on August 14, 2026, under a pre-arranged Rule 10b5-1 Plan. Following this transaction, Brown directly holds 102,953 shares, which includes 74,753 unvested restricted stock units. The sale was executed as part of an orderly disposition plan adopted in November 2025.
DataMeds AI's $6.5M Funding Precedes a Planned App Launch
DataMeds AI (NASDAQ:MEDS) reported Q2 2026 financials, showing a net revenue of $1.78 million and a net loss of $18.36 million, alongside a successful raise of $6.5 million in funding. The company also restructured $14.5 million in debt and ended the quarter with $2.46 million in cash. DataMeds AI plans to launch its "Health Lives Here" consumer app in September 2026, targeting GLP-1 patients in rural communities, and is moving forward with a strategic "Datavault Transaction" to expand its PharmacyChain license and acquire biometric patents.
Dexcom stock trades at premium valuation as margins improve and targets rise
Dexcom stock is trading at a premium valuation, consolidating near $89 after a significant year-to-date gain, supported by improved second-quarter margins and higher consensus price targets. The company's strong financial performance, particularly in its continuous glucose monitoring business, justifies its higher forward price-to-earnings multiple compared to industry benchmarks. Analysts maintain a "Moderate Buy" rating, and new institutional investments signal continued confidence in Dexcom's growth trajectory despite its current valuation.
Biotech Stocks At 52-Week Highs - ETON +44%, DXCM, ORKA, CON, ATAI
Several biotech and healthcare stocks, including Eton Pharmaceuticals, DexCom, Oruka Therapeutics, Concentra Group Holdings, and AtaiBeckley, reached 52-week highs on August 14, 2026. This performance was driven by positive quarterly reports, strong sales growth, new drug approvals, and, in the case of AtaiBeckley, an acquisition agreement with Eli Lilly and Company. Companies like Eton and DexCom reported significant revenue growth, while Oruka and AtaiBeckley are advancing promising drug candidates in clinical trials.
OneDigital Investment Advisors LLC Makes New $11.53 Million Investment in DexCom, Inc. $DXCM
OneDigital Investment Advisors LLC has made a new $11.53 million investment in DexCom, Inc. (NASDAQ:DXCM), purchasing 171,242 shares. This comes as institutional investors collectively own 97.75% of the company, and Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $88.71. Despite positive quarterly earnings exceeding expectations, company insiders have sold nearly 100,000 shares in the past 90 days.
Nippon Life Global Investors Americas Inc. Buys Shares of 53,400 DexCom, Inc. $DXCM
Nippon Life Global Investors Americas Inc. has acquired a new position of 53,400 shares in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, valued at approximately $3.596 million. Other institutional investors have also adjusted their stakes in the company, while DexCom insiders have sold shares totaling over $7 million in the last ninety days. DexCom's stock has a market cap of $33.87 billion, and analysts have given it a "Moderate Buy" rating with a consensus target price of $88.71.
DexCom, Inc. (DXCM): Investor Outlook on a Leading Medical Device Innovator with Strong Buy Ratings
DexCom, Inc. (DXCM) is highlighted as a leading medical device innovator specializing in continuous glucose monitoring (CGM) systems, with strong buy ratings from analysts. Despite a recent price dip, the company shows resilience, strong revenue growth, robust return on equity, and significant free cash flow. DexCom's commitment to innovation and expansion of its product offerings, including the Dexcom G7, Dexcom ONE+, and Stelo, positions it favorably for continued market leadership in diabetes management technology.
Oppenheimer & Co. Inc. Reduces Stock Holdings in Medtronic PLC $MDT
Oppenheimer & Co. Inc. decreased its stake in Medtronic PLC by 7.1% during the second quarter, selling 13,947 shares to hold a total of 183,078 shares valued at $14.32 million. Despite this reduction, other institutional investors have increased their holdings in Medtronic. The company recently announced a dividend increase to $0.72 per share, and analysts have a "Moderate Buy" rating with an average target price of $98.83.
Massachusetts Financial Services Co. MA Has $1.55 Billion Stock Holdings in Medtronic PLC $MDT
Massachusetts Financial Services Co. MA reduced its stake in Medtronic PLC by 7.3% in the second quarter, now holding 19.87 million shares valued at $1.55 billion. Medtronic reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. The company also received several analyst upgrades, with a consensus target price of $98.83.
Daymark Wealth Partners LLC Sells 35,341 Shares of Medtronic PLC $MDT
Daymark Wealth Partners LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 66.1% in the second quarter, selling 35,341 shares and holding 18,109 shares valued at $1.417 million. Despite this, other major institutional investors like Vanguard Group Inc., State Street Corp, and JPMorgan Chase & Co. increased their positions in Medtronic. The article also notes an insider sale by EVP Harry Skip Kiil and summarizes various analyst ratings and financial performance data for Medtronic, including a recent dividend increase.
DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates
DexCom (DXCM) has seen a modest increase in its modelled fair value from US$91.64 to US$94.12 following positive Q2 2026 execution and new clinical data. Analysts from several firms have raised price targets, citing strong margins, expanding reimbursement opportunities, and a robust product pipeline. However, some bearish sentiment exists regarding the broader medical technology sector.
Pictet Asset Management Holding SA Sells 83,154 Shares of Medtronic PLC $MDT
Pictet Asset Management Holding SA reduced its stake in Medtronic PLC by 6.8% in the second quarter, selling 83,154 shares and now owning 1,147,659 shares valued at $89.79 million. Other institutional investors also adjusted their holdings in Medtronic. The article also covers analyst ratings, Medtronic's financial performance, and a recent dividend increase.
Calamos Advisors LLC Reduces Stock Holdings in Medtronic PLC $MDT
Calamos Advisors LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 29.4% in the second quarter, selling 177,132 shares and retaining 425,833 shares valued at $33.3 million. Despite this, institutional investors collectively own 82.06% of the company, which recently reported strong quarterly revenues and adjusted EPS exceeding expectations. Medtronic also increased its quarterly dividend to $0.72 per share, and analysts maintain a "Moderate Buy" rating with a consensus price target of $98.83.
Bridgewater Advisors Inc. Invests $1.08 Million in DexCom, Inc. $DXCM
Bridgewater Advisors Inc. has acquired a new position in DexCom, Inc. (NASDAQ:DXCM) by purchasing 12,347 shares valued at approximately $1.08 million during the second quarter. This investment is part of a broader trend of institutional interest, with several other firms increasing their stakes in the medical device company. Analysts currently rate DexCom as a "Moderate Buy" with an average target price of $88.71, and the company recently reported strong quarterly earnings, beating analyst estimates.
43,005 Shares in DexCom, Inc. $DXCM Bought by SWS Partners
SWS Partners recently acquired 43,005 shares of DexCom, Inc. ($DXCM) during the second quarter, valued at approximately $2.9 million, making them a new institutional investor in the medical device company. Despite some insider selling activity, which was conducted under pre-arranged trading plans, analysts generally maintain a "Moderate Buy" rating for DexCom with a consensus price target of $88.71. The company also surpassed its quarterly earnings expectations, reporting strong revenue growth.
Swiss Life Asset Management Ltd Takes $63.27 Million Position in Medtronic PLC $MDT
Swiss Life Asset Management Ltd has acquired a significant new stake in Medtronic PLC, purchasing over 800,000 shares valued at approximately $63.27 million. This move comes as Medtronic reports strong quarterly earnings, beating analyst estimates with $9.81 billion in revenue and $1.55 EPS, and increases its quarterly dividend to $0.72 per share. Analysts maintain a "Moderate Buy" rating for Medtronic, with a consensus price target of $98.83.
Ethic Inc. Increases Stock Holdings in Medtronic PLC $MDT
Ethic Inc. increased its holdings in Medtronic PLC by 8.7% in the second quarter, bringing its total ownership to 158,467 shares valued at $12.397 million. Other institutional investors also adjusted their stakes in Medtronic. The company recently reported strong quarterly earnings, beating consensus estimates, and announced an increased quarterly dividend of $0.72 per share.
ETFs Investing in DexCom, Inc. Stocks
This article provides a list of Exchange Traded Funds (ETFs) that hold DexCom, Inc. stocks, sorted by market value. It highlights how these funds can make investing in stocks more accessible and offer diversified opportunities with lower risk. The list includes various ETFs from different issuers, detailing their market value, weight of DexCom stock, management style, expense ratio, assets under management, and recent price performance.
DexCom Inc. stock underperforms Friday when compared to competitors
Shares of DexCom Inc. (DXCM) fell by 1.89% to $89.75 on Friday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. This drop ended a six-day winning streak for the company's stock.
Florida Trust Wealth Management Co Sells 19,058 Shares of Medtronic PLC $MDT
Florida Trust Wealth Management Co significantly reduced its stake in Medtronic PLC, selling 19,058 shares and retaining 35,841 shares valued at $2.8 million. This comes as Medtronic exceeded analyst estimates with its quarterly earnings and revenue, and increased its dividend. The company maintains a "Moderate Buy" rating from analysts with an average price target of $98.83.
Asset Management One Co. Ltd. Cuts Stock Holdings in Medtronic PLC $MDT
Asset Management One Co. Ltd. significantly reduced its stake in Medtronic PLC by 3.9% in the second quarter, selling 22,946 shares but still holding 563,263 shares valued at approximately $44.1 million. Despite this, institutional investors collectively own 82.06% of Medtronic, and analysts maintain a "Moderate Buy" rating with an average price target of $98.83. The company recently reported strong quarterly revenue and adjusted earnings, and increased its quarterly dividend to $0.72 per share.
Atria Investments Inc Has $12.24 Million Position in Medtronic PLC $MDT
Atria Investments Inc increased its stake in Medtronic PLC (NYSE:MDT) by 12.1% in the second quarter, bringing their total holdings to 156,519 shares valued at $12.24 million. Medtronic recently announced an increase in its quarterly dividend to $0.72 per share, and analysts have a "Moderate Buy" consensus rating with a target price of $98.83.
Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs
Dexcom director Nicholas Augustinos reported a gift of 1,075 shares of common stock to a charitable donor-advised fund on August 12, 2026. These shares were held indirectly through the Kirschner/Augustinos Revocable Trust, which now holds 37,382 shares. Additionally, Augustinos holds 5,575 unvested restricted stock units granted on May 28, 2026, set to vest on the earlier of their one-year anniversary or the company's 2027 Annual Meeting of Stockholders.
DexCom Inc (MIL:1DXCM) Stock Price, Trades & News
This page provides a detailed overview of DexCom Inc (MIL:1DXCM) stock, including its current price, market capitalization, P/E and P/B ratios, and key financial metrics. It highlights the company's financial strength, growth rank, profitability, and GF Value rank, along with recent news and upcoming earnings dates. The company designs and commercializes continuous glucose monitoring systems for diabetic patients.
Inside Senseonics’ commercial overhaul and what’s next
Senseonics, a diabetes tech company, has taken over the commercialization and distribution of its Eversense 365 continuous glucose monitor (CGM) from Ascensia Diabetes Care, integrating sales and marketing teams in-house. This move aims to accelerate growth and allows for greater control over its business, as evidenced by a record second quarter with revenue more than doubling to $14.5 million. The company is also working on a fully implantable, year-long sensor that communicates directly with a phone, and anticipates Medicare expanding CGM coverage to non-insulin-dependent Type 2 diabetes patients, which would significantly expand their market.
Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating
Citigroup has increased its price target for DexCom (DXCM) shares to $105 from $88, while reiterating a Buy rating on the stock. This adjustment reflects a more optimistic outlook from the firm regarding the medical equipment company. DexCom specializes in continuous glucose monitoring systems for diabetes management.
SBC Medical Group (SBC) Q2 2026: profit jumps, cash flow turns positive
SBC Medical Group reported strong Q2 2026 results with total revenues increasing to $49.19 million, up from $43.36 million a year prior, primarily driven by related-party revenues. The company saw a significant jump in net income attributable to shareholders, reaching $10.69 million compared to $2.46 million in Q2 2025, and operating cash flow turned positive, providing $31.74 million in the first half of 2026, a substantial improvement from a $6.41 million use in the prior year. Despite a modest decline in first-half net income compared to 2025, robust liquidity with $184.31 million in cash and cash equivalents underscores a solid financial position.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) saw its stock rise by 1.42% to $90.80 on Wednesday, marking its fifth consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04% on the same mixed trading day.
